ArticleBiogerontology2025
FOXO3a upregulates DNA repair activities by transcriptional activation of target genes and provides the resistance to gamma radiation and the extension of lifespan in mouse.
Article in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
To verify whether DNA repair is regulated by FOXO3a, a tet-on flag-h-FOXO3a transgenic mice were used. RT-q-PCR and western blot analysis showed that the mRNA and protein levels of flag-h-FOXO3a, XRCC4, XPC, APE1 and MSH2 increased dose dependently by doxycycline. DNA repair activities like non-homologous end joining (NHEJ), nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR) also increased in a doxycycline dose dependent manner. MEF (mouse embryonic fibroblast) cells of the transgenic mouse were transfected with human XRCC4/XPC/APE1/MSH2 promoter-pGL3 basic vectors. Promoter assay and ChIP (chromatin immunoprecipitation) assay showed increased promoter activity and interactions of FOXO3a to FOXO consensus sites. The results indicate that XRCC4, XPC, APE1, and MSH2 are transcriptional target genes of FOXO3a and activities of NHEJ, NER, BER and MMR are regulated probably via transcriptional activation of XRCC4, XPC, APE1 and MSH2 by FOXO3a. FOXO3a overexpression in MEF cells and tet-on flag-h-FOXO3a transgenic mouse exhibited high resistance to gamma radiation. Small intestine showed less damage and apoptosis in doxycycline-treated mice. The median and maximum lifespan of the doxycycline-treated transgenic mice increased by about 30%. The results suggest that FOXO3a overexpression provide protection against gamma radiation and lifespan extension possibly via activation of DNA repair.
Indexed as
Identifiers
41148397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.